Cargando…

FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo

SIMPLE SUMMARY: Late diagnosis of ovarian cancer is a major reason for the high mortality rate of this tumor entity. The time to determine tumor susceptibility to treatment is scarce and resistance to therapy occurs very frequently. Here, we aim for a model system that can determine tumor response t...

Descripción completa

Detalles Bibliográficos
Autores principales: Brückner, Luzie, Reinshagen, Annika, Hoang, Ngoc Anh, Höhn, Anne Kathrin, Lordick, Florian, Bechmann, Ingo, Aktas, Bahriye, Nel, Ivonne, Kallendrusch, Sonja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956612/
https://www.ncbi.nlm.nih.gov/pubmed/33668819
http://dx.doi.org/10.3390/cancers13050956
_version_ 1783664476111765504
author Brückner, Luzie
Reinshagen, Annika
Hoang, Ngoc Anh
Höhn, Anne Kathrin
Lordick, Florian
Bechmann, Ingo
Aktas, Bahriye
Nel, Ivonne
Kallendrusch, Sonja
author_facet Brückner, Luzie
Reinshagen, Annika
Hoang, Ngoc Anh
Höhn, Anne Kathrin
Lordick, Florian
Bechmann, Ingo
Aktas, Bahriye
Nel, Ivonne
Kallendrusch, Sonja
author_sort Brückner, Luzie
collection PubMed
description SIMPLE SUMMARY: Late diagnosis of ovarian cancer is a major reason for the high mortality rate of this tumor entity. The time to determine tumor susceptibility to treatment is scarce and resistance to therapy occurs very frequently. Here, we aim for a model system that can determine tumor response to (I) study novel drugs and (II) enhance patient stratification. Tissue specimens (n = 10) were acquired from fresh surgical samples. Tissue cultures were cultivated and treated with clinically relevant therapeutics and an FOXM1 inhibitor for 3–6 days. The transcription factor FOXM1 is a key regulator of tumor survival affecting multiple cancerogenic target genes. Gene expression of FOXM1 and its targets BRCA1/2 and RAD51 were investigated together with tumor susceptibility. Tissue cultures successfully demonstrated the individual benefit of FOXM1 inhibition and revealed the potency of the complex model system for oncological research. ABSTRACT: Diagnosis in an advanced state is a major hallmark of ovarian cancer and recurrence after first line treatment is common. With upcoming novel therapies, tumor markers that support patient stratification are urgently needed to prevent ineffective therapy. Therefore, the transcription factor FOXM1 is a promising target in ovarian cancer as it is frequently overexpressed and associated with poor prognosis. In this study, fresh tissue specimens of 10 ovarian cancers were collected to investigate tissue cultures in their ability to predict individual treatment susceptibility and to identify the benefit of FOXM1 inhibition. FOXM1 inhibition was induced by thiostrepton (3 µM). Carboplatin (0.2, 2 and 20 µM) and olaparib (10 µM) were applied and tumor susceptibility was analyzed by tumor cell proliferation and apoptosis in immunofluorescence microscopy. Resistance mechanisms were investigated by determining the gene expression of FOXM1 and its targets BRCA1/2 and RAD51. Ovarian cancer tissue was successfully maintained for up to 14 days ex vivo, preserving morphological characteristics of the native specimen. Thiostrepton downregulated FOXM1 expression in tissue culture. Individual responses were observed after combined treatment with carboplatin or olaparib. Thus, we successfully implemented a complex tissue culture model to ovarian cancer and showed potential benefit of combined FOXM1 inhibition.
format Online
Article
Text
id pubmed-7956612
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-79566122021-03-16 FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo Brückner, Luzie Reinshagen, Annika Hoang, Ngoc Anh Höhn, Anne Kathrin Lordick, Florian Bechmann, Ingo Aktas, Bahriye Nel, Ivonne Kallendrusch, Sonja Cancers (Basel) Article SIMPLE SUMMARY: Late diagnosis of ovarian cancer is a major reason for the high mortality rate of this tumor entity. The time to determine tumor susceptibility to treatment is scarce and resistance to therapy occurs very frequently. Here, we aim for a model system that can determine tumor response to (I) study novel drugs and (II) enhance patient stratification. Tissue specimens (n = 10) were acquired from fresh surgical samples. Tissue cultures were cultivated and treated with clinically relevant therapeutics and an FOXM1 inhibitor for 3–6 days. The transcription factor FOXM1 is a key regulator of tumor survival affecting multiple cancerogenic target genes. Gene expression of FOXM1 and its targets BRCA1/2 and RAD51 were investigated together with tumor susceptibility. Tissue cultures successfully demonstrated the individual benefit of FOXM1 inhibition and revealed the potency of the complex model system for oncological research. ABSTRACT: Diagnosis in an advanced state is a major hallmark of ovarian cancer and recurrence after first line treatment is common. With upcoming novel therapies, tumor markers that support patient stratification are urgently needed to prevent ineffective therapy. Therefore, the transcription factor FOXM1 is a promising target in ovarian cancer as it is frequently overexpressed and associated with poor prognosis. In this study, fresh tissue specimens of 10 ovarian cancers were collected to investigate tissue cultures in their ability to predict individual treatment susceptibility and to identify the benefit of FOXM1 inhibition. FOXM1 inhibition was induced by thiostrepton (3 µM). Carboplatin (0.2, 2 and 20 µM) and olaparib (10 µM) were applied and tumor susceptibility was analyzed by tumor cell proliferation and apoptosis in immunofluorescence microscopy. Resistance mechanisms were investigated by determining the gene expression of FOXM1 and its targets BRCA1/2 and RAD51. Ovarian cancer tissue was successfully maintained for up to 14 days ex vivo, preserving morphological characteristics of the native specimen. Thiostrepton downregulated FOXM1 expression in tissue culture. Individual responses were observed after combined treatment with carboplatin or olaparib. Thus, we successfully implemented a complex tissue culture model to ovarian cancer and showed potential benefit of combined FOXM1 inhibition. MDPI 2021-02-25 /pmc/articles/PMC7956612/ /pubmed/33668819 http://dx.doi.org/10.3390/cancers13050956 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brückner, Luzie
Reinshagen, Annika
Hoang, Ngoc Anh
Höhn, Anne Kathrin
Lordick, Florian
Bechmann, Ingo
Aktas, Bahriye
Nel, Ivonne
Kallendrusch, Sonja
FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title_full FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title_fullStr FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title_full_unstemmed FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title_short FOXM1 Inhibition in Ovarian Cancer Tissue Cultures Affects Individual Treatment Susceptibility Ex Vivo
title_sort foxm1 inhibition in ovarian cancer tissue cultures affects individual treatment susceptibility ex vivo
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956612/
https://www.ncbi.nlm.nih.gov/pubmed/33668819
http://dx.doi.org/10.3390/cancers13050956
work_keys_str_mv AT brucknerluzie foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT reinshagenannika foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT hoangngocanh foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT hohnannekathrin foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT lordickflorian foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT bechmanningo foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT aktasbahriye foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT nelivonne foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo
AT kallendruschsonja foxm1inhibitioninovariancancertissueculturesaffectsindividualtreatmentsusceptibilityexvivo